448964-30-5

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activities. Its antifungal, antibacterial, and anticancer properties make it a promising candidate for the development of new drugs to combat infections and cancer.
Used in Agrochemical Industry:
In the agrochemical industry, 5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one is utilized as a building block in the creation of novel agrochemicals. Its biological activities can be harnessed to develop pesticides or fungicides that protect crops from various pathogens.
Used in Organic Electronics and Polymer Science:
5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one is used as a component in the development of new materials for organic electronics and polymer science. Its unique structural and electronic properties contribute to the advancement of organic semiconductors, which have applications in flexible electronics, solar cells, and other emerging technologies.
Used in Natural Product Synthesis:
5,6-Dihydro-2H-indeno[5,6-b]furan-7(3H)-one is also used as a building block in the synthesis of natural products, leveraging its potential biological activities to create new compounds with therapeutic or ecological benefits.

Upstream product

• 496-16-2 2.3-dihydrobenzofuran 
• 55745-70-5 2,3-dihydro-benzofuran-5-carbaldehyde 
• 198707-57-2 3-(2,3-dihydro-1-benzofuran-5-yl)prop-2-enoic acid 
• 215057-28-6 3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid 
• 203505-84-4 3-(2,3-dihydro-1-benzofuran-5-yl)-2-propenoic acid 

Downstream Products

• 448964-31-6 2-(2,3,5,6-tetrahydro-7H-indeno[5,6-b]furan-7-ylidene)acetonitrile 
• 448964-32-7 2-(3,5,6,7-tetrahydro-2H-indeno[5,6-b]furan-7-yl)ethylamine 
• 1412271-99-8 C₂₆H₂₂BrN₂O₂⁽¹⁺⁾*Br^(1-) 
• 1412271-87-4 C₂₇H₂₅N₂O₃⁽¹⁺⁾*Br^(1-) 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND USES

The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

Dihydrofuran and yinyin alkane - imidazole salt compound and its preparation method

The invention discloses a series of dihydrofuran indenoane-imidazole salts compounds and a preparation method thereof. The preparation method comprises the following steps of: carrying out Vilsmeier reaction and Perskin reaction on 2,3-dihydrobenzofuran taken as a raw material; reducing palladium/carbon in an acetic acid to 5-propionic acid dihydrobenzofuran and forming acyl chloride with thionyl chloride; carrying out intramolecular Friedel-Crafts reaction and reducing in an alcohol solution by using sodium borohydride to obtain dihydrofuran indenoanol; forming a chloride in a toluene solution with the thionyl chloride; and reflowing and reacting with imidazole or 2-methyl imidazole or 2-ethyl imidazole or benzimidazole in acetonitrile or a toluene solvent to synthesize 1-(dihydrofuran indenoane) imidazole, and reacting with a halide on the above basis to synthesize the compound. According to the dihydrofuran indenoane-imidazole salts compounds and the preparation method thereof, pharmacophores with obvious tumor resisting activity in natural products are used as precursors to carry out designing and synthesizing on anti-tumor medicine molecule, and when an imidazole structure unit in a synthesized compound is the benzimidazole, particularly a naphthoyl methyl imidazole salts compound, the compound has very good in-vitro anticancer physiological activity.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Novel tricyclic indeno[5,6-b]furan-imidazole hybrid compounds: Design, synthesis and antitumor activity

A series of novel hybrid compounds between tricyclic indeno[5,6-b]furan and imidazole has been prepared and evaluated in vitro against a panel of human tumor cell lines. The results suggest that the existence of benzimidazole ring and substitution of the imidazolyl-3-position with a naphthylacyl group were vital for modulating cytotoxic activity. In particular, hybrid compound 26 was found to be the most potent compound against 5 strains human tumor cell lines and more active than cisplatin (DDP), while compound 18 was more selective towards breast carcinoma (MCF-7) and colon carcinoma (SW480) with IC50 value 3.4-fold and 4.3-fold more sensitive to DDP.

Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists

To develop a new therapeutic agent for sleep disorders, we synthesized a novel series of tricyclic indan derivatives and evaluated them for their binding affinity to melatonin receptors. In our previous paper, we proposed a conformation of the methoxy group favorable for the binding of the MT1 receptor. To fix the methoxy group in an active conformation, we decided to synthesize conformationally restricted tricyclic indan analogues with the oxygen atom in the 6-position incorporated into a furan, 1,3-dioxane, oxazole, pyran, morpholine, or 1,4-dioxane ring system. Among these compounds, indeno[5,4-b]furan analogues were found to be the most potent and selective MT1 receptor ligands and to have superior metabolic stability. The optimization of substituents led to (S)-(-)-22b, which showed very strong affinity for human MT1 (Ki = 0.014 nM), but no significant affinity for hamster MT3 (Ki = 2600 nM) or other neurotransmitter receptors. The pharmacological effects of (S)-(-)-22b were studied in experimental animals, and it was found that a dose of 0.1 mg/kg, po promoted a sleep in freely moving cats, as demonstrated by a decrease in wakefulness and increases in slow wave sleep and rapid eye movement sleep, which lasted for 6 h after administration. Melatonin (1 mg/kg, po) also had a sleep-promoting effect, though it lasted only 2 h. A new chiral method for the synthesis of (S)-(-)-22b starting from 60, which was prepared from 59 employing asymmetric hydrogenation with the (S)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl-Ru complex, was developed. (S)-(-)-22b (TAK-375) is currently under clinical trial for the treatment of insomnia and circadian rhythm disorders.